Who are Taxane plus Intermittent Capecitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Albumin-bound Paclitaxel plus S-1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/taxane-plus-intermittent-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Taxane plus Intermittent Capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Taxane plus Intermittent Capecitabine (Taxane plus Intermittent Capecitabine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy (taxane + fluoropyrimidine). Area: Oncology.

phase 3 Combination chemotherapy (taxane + fluoropyrimidine) Microtubules (taxane); thymidylate synthase (capecitabine/5-FU) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Taxane plus Intermittent Capecitabine (Taxane plus Intermittent Capecitabine) — Sun Yat-sen University. A combination regimen that uses taxane chemotherapy to disrupt microtubule dynamics and kill rapidly dividing cancer cells, paired with intermittent capecitabine to provide additional cytotoxic activity and potentially improve tolerability through dosing intermittency.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Taxane plus Intermittent Capecitabine TARGET	Taxane plus Intermittent Capecitabine	Sun Yat-sen University	phase 3	Combination chemotherapy (taxane + fluoropyrimidine)	Microtubules (taxane); thymidylate synthase (capecitabine/5-FU)
Albumin-bound Paclitaxel plus S-1	Albumin-bound Paclitaxel plus S-1	Huazhong University of Science and Technology	phase 3	Combination chemotherapy (taxane + fluoropyrimidine)	Microtubules (paclitaxel); Thymidylate synthase (S-1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy (taxane + fluoropyrimidine) class)

Huazhong University of Science and Technology · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Taxane plus Intermittent Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/taxane-plus-intermittent-capecitabine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab